tunodafil hydrochloride

**Tunodafil hydrochloride** is an oral **small-molecule phosphodiesterase type 5 inhibitor** being developed by **Yangtze River Pharmaceutical Group** for **erectile dysfunction**. Public clinical-trial records describe **tunodafil hydrochloride tablets** in randomized, double-blind, placebo-controlled studies in men with erectile dysfunction, including a Phase 3 program, and published clinical pharmacology work has evaluated its interaction with alcohol as well as drug-drug interactions with ritonavir and omeprazole. The pharmacology is consistent with other PDE5 inhibitors: inhibition of PDE5 increases cyclic guanosine monophosphate signaling in corpus cavernosum smooth muscle, promoting vasodilation and facilitating penile erection in response to sexual stimulation.

Other names

tunodafilyonkenafil hydrochlorideyonkenafilyoukenafil